- Report
- March 2026
- 476 Pages
Global
From €5258EUR$5,850USD£4,565GBP
- Report
- March 2026
- 141 Pages
Global
From €5258EUR$5,850USD£4,565GBP
- Report
- March 2026
- 466 Pages
Global
From €5258EUR$5,850USD£4,565GBP
- Report
- March 2026
- 565 Pages
Global
From €5258EUR$5,850USD£4,565GBP
- Report
- March 2026
- 283 Pages
Global
From €5258EUR$5,850USD£4,565GBP
- Report
- March 2026
- 673 Pages
Global
From €5258EUR$5,850USD£4,565GBP
- Report
- March 2026
- 676 Pages
Global
From €5258EUR$5,850USD£4,565GBP
- Report
- March 2026
- 392 Pages
Global
From €5258EUR$5,850USD£4,565GBP
- Report
- March 2026
- 553 Pages
Global
From €5258EUR$5,850USD£4,565GBP
- Report
- March 2026
- 179 Pages
Global
From €5258EUR$5,850USD£4,565GBP
- Report
- March 2026
- 166 Pages
Global
From €5258EUR$5,850USD£4,565GBP
- Report
- March 2026
- 390 Pages
Global
From €5258EUR$5,850USD£4,565GBP
- Report
- March 2026
- 220 Pages
Global
From €5258EUR$5,850USD£4,565GBP
- Report
- March 2026
- 245 Pages
Global
From €5258EUR$5,850USD£4,565GBP
- Report
- March 2026
- 373 Pages
Global
From €5258EUR$5,850USD£4,565GBP
- Report
- March 2026
- 244 Pages
Global
From €5258EUR$5,850USD£4,565GBP
- Report
- March 2026
- 324 Pages
Global
From €5258EUR$5,850USD£4,565GBP
- Report
- March 2026
- 184 Pages
Global
From €5258EUR$5,850USD£4,565GBP
- Report
- March 2026
- 193 Pages
Global
From €5258EUR$5,850USD£4,565GBP
- Report
- March 2026
- 246 Pages
Global
From €5258EUR$5,850USD£4,565GBP

The Biosimilar market is a subset of the biotechnology industry that focuses on the development and production of biologic drugs that are similar to existing biologic drugs. Biosimilars are created using a process called recombinant DNA technology, which involves the manipulation of genetic material to create a drug that is similar to an existing biologic drug. Biosimilars are typically used to treat chronic conditions such as cancer, rheumatoid arthritis, and multiple sclerosis. Biosimilars are typically cheaper than their brand-name counterparts, making them an attractive option for patients and healthcare providers.
Some companies in the Biosimilar market include Amgen, Biocon, Celltrion, Dr. Reddy's Laboratories, Mylan, Pfizer, Sandoz, and Teva Pharmaceuticals. Show Less Read more